Chengdu Kanghua Biological Products (300841.SZ): Recombinant six-valent norovirus vaccine (Saccharomyces cerevisiae) receives clinical trial approval notification.

Chengdu Kanghua Biological Products (300841.SZ) announced that recently, the company's research and development of recombinant hexavalent norovirus vaccine (baker's yeast) has obtained the "Notice of Approval for Drug Clinical Trial" issued by the National Medical Products Administration, allowing the product to conduct clinical trials. After review, the recombinant hexavalent norovirus vaccine (baker's yeast) accepted on September 25, 2024, meets the relevant requirements for drug registration and is approved to conduct clinical trials for the prevention of acute gastroenteritis caused by genotype infection.